<DOC>
	<DOCNO>NCT00483223</DOCNO>
	<brief_summary>The purpose research study : - Determine effective cisplatin carboplatin slow time take ER negative , PR negative , HER2 negative breast cancer progress . Cisplatin carboplatin anti-cancer chemotherapy drug stop cancer cell grow abnormally use treat cancer . - Evaluate new biomarker help determine breast cancer likely respond cisplatin chemotherapy The hypothesis Triple Negative metastatic breast cancer may particularly sensitive platinum , subgroup patient may marker tumor predict response .</brief_summary>
	<brief_title>Platinum Triple-Negative Metastatic Breast Cancer Evaluation p63/p73 Biomarker Response</brief_title>
	<detailed_description>This study Phase 2 study design evaluate cisplatin/carboplatin first second line therapy metastatic triple negative ( ER negative , PR negative , Her2 Negative ) breast cancer evaluate expression p63/p73 biomarker predict response . - Participants give cisplatin carboplatin infusion intravenously first day treatment cycle . Each treatment cycle last 3 week . Treating physician select agent 41 patient cohort . Final primary endpoint analysis use combine cis/carbo result . - During treatment cycle participant physical exam ( include weight vital sign ) ask general question health medication may take , well specific question side effect may experience receive study treatment . - During every treatment cycle participant standard blood test check blood count , liver kidney function , blood marker particular type cancer . - CT scan take participant tumor every 2 3 cycle assess response tumor cisplatin . - Participants study long tolerate study treatment disease get bad . - Participants require sample original tumor send Massachusetts General Hospital correlative study , sample metastatic diagnostic biopsy . - Patients accessible tumor ask provide optional metastatic tumor biopsy correlative study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm invasive breast cancer stage IV disease , accord AJCC 6th edition , either biopsy proven unequivocal evidence metastatic disease physical examination radiological study All tumor must ER , PGR HER2negative 18 year age old Paraffin tissue block require primary tumor tissue diagnostic metastatic biopsy time relapse Measurable disease RECIST Performance status 0,1 2 ECOG criterion Life expectancy great 12 week Normal organ bone marrow function document within 14 day prior enrollment define protocol More 1 prior chemotherapy treatment recurrent metastatic breast cancer Prior treatment cisplatin , carboplatin , platinum chemotherapy agent Active brain metastasis unevaluated neurological symptom suggestive brain metastasis Intercurrent illness major medical condition comorbid condition might affect study participation Significant history uncontrolled cardiac disease uncontrolled hypertension , unstable angina , recent myocardial infarction , uncontrolled congestive heart failure , cardiomyopathy either symptomatic asymptomatic decrease ejection fraction &lt; 45 % Renal dysfunction cisplatin dose would either require dose modification would consider unsafe Pregnant nursing woman History malignancy treat curative intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ER negative</keyword>
	<keyword>PgR negative</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>cisplatin</keyword>
	<keyword>carboplatinum</keyword>
	<keyword>platinum</keyword>
	<keyword>p63</keyword>
	<keyword>p73</keyword>
</DOC>